Printed from www.actionpf.org

Healthcare professionals: make a referral
Take part in research

Find a research study

Ask your healthcare team about taking part in research

Explore the Study Finder to learn about research that is happening in the UK today. You may be able to take part.

Need help? Take a look at our information guide.

Are you a researcher currently recruiting participants in the UK? If you would like your study included on this page, please complete this online form.

Show filter options
Reset filters
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis
Healthy volunteers
Northern Ireland
Wales
Scotland
England
Further explanation
Trial phase

There are 3 main phases of clinical trials:

  • Phase 1 is the earliest stage of research, where there is often a focus on understanding if the treatment is safe or if it causes any side effects.
  • Phase 2 still focuses on safety and side effects, but also tries to find out more about what is the best dose.
  • Phase 3 often compares the new treatment to existing treatments or lookalike medications.

As drugs or interventions move into the different phases, the number of people taking part will increase. Not all studies will make it to the later phases, especially if the intervention is not found to be safe or effective in phase 1 and 2.

Further explanation
Trial phase

There are 3 main phases of clinical trials:

  • Phase 1 is the earliest stage of research, where there is often a focus on understanding if the treatment is safe or if it causes any side effects.
  • Phase 2 still focuses on safety and side effects, but also tries to find out more about what is the best dose.
  • Phase 3 often compares the new treatment to existing treatments or lookalike medications.

As drugs or interventions move into the different phases, the number of people taking part will increase. Not all studies will make it to the later phases, especially if the intervention is not found to be safe or effective in phase 1 and 2.

Further explanation
Trial phase

There are 3 main phases of clinical trials:

  • Phase 1 is the earliest stage of research, where there is often a focus on understanding if the treatment is safe or if it causes any side effects.
  • Phase 2 still focuses on safety and side effects, but also tries to find out more about what is the best dose.
  • Phase 3 often compares the new treatment to existing treatments or lookalike medications.

As drugs or interventions move into the different phases, the number of people taking part will increase. Not all studies will make it to the later phases, especially if the intervention is not found to be safe or effective in phase 1 and 2.

Further explanation
Open-label extension

Some studies offer an extension phase of research, where people continue to receive the new drug or therapy after the initial trial has finished. The extension phase is often ‘open-label’, which means that you will know that you are receiving the active treatment .

Further explanation
Can continue on antifibrotics

Within studies, there are different requirements that someone must meet, to be able to take part. Some studies recruit people who are taking antifibrotic medications, including nintedanib or pirfenidone. However, in other studies people taking part must not be taking antifibrotic medication.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
0
 result/s
Tag

How does the body respond to a new drug, LTI-03?

Results available
Upcoming
Recruiting
Closed
21 days
participation
21 days
participation
A study looking at how a new drug, called LTI-03, affects people with IPF

This clinical trial is designed to see if a new drug called LTI-03 can help people with IPF.‍

‘The aim is to understand if the study drug is well tolerated and how it affects the body.’

People affected by IPF currently have limited treatment options to slow the progression of disease. New research studies are needed to learn about better treatment options.

Taking a drug
Hospital visits
England
Scotland
I
Idiopathic Pulmonary Fibrosis (IPF)

How do people with lung fibrosis respond to a new drug, BMS-986278?

Results available
Upcoming
Recruiting
Closed
26 weeks
participation
26 weeks
participation
A phase 2 study looking at a new drug, BMS-986278 for people with lung fibrosis

Researchers discovered that there is a marker, called lysophospholipid lysophosphatidic acid (LPA), within the lungs that is shown to be increased and related to the development of pulmonary fibrosis.

Injury to the lungs stimulates this to be made, ultimately leading to scarring of the lungs. A new drug, BMS-986278, which is thought to block this process could help people with pulmonary fibrosis.

In this study, researchers aim to find out if the new drug is safe and effective to potentially help treat pulmonary fibrosis.

Taking a drug
Hospital visits
Can continue on antifibrotics
England
Scotland
II
Other forms of pulmonary fibrosis
Idiopathic Pulmonary Fibrosis (IPF)

Can morphine reduce IPF cough?

Results available
Upcoming
Recruiting
Closed
7 weeks
participation
7 weeks
participation
PAciFY Study: A clinical trial investigating the effects of morphine on IPF cough

The cause of cough in pulmonary fibrosis is not fully understood, but researchers around the world are trying to better understand and treat this distressing symptom. The PAciFY Study is investigating whether morphine (a widely used strong painkiller) can reduce the amount IPF patients’ cough and improve their quality of life.

Taking a drug
Hybrid
Open-label extension
England
III
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis

Zephyrus II: Is Pamrevlumab safe and effective for people with IPF?

Results available
Upcoming
Recruiting
Closed
Up to 48 weeks
participation
Up to 48 weeks
participation
Zephyrus II: Phase 3 study investigating the safety and effectiveness of a new drug, Pamrevlumab, for patients with IPF

The Zephyrus II study is randomised control trial where patients will receive a drip (intravenous infusion) of either the drug, Pamrevlumab, or a placebo, every 3 weeks. There are a total of up to 17 infusions over a period of 48 weeks.

The aim of the study is to understand if the effect of the new drug for people with IPF, and if there is an impact on lung function over time.

Taking a drug
Hospital visits
Open-label extension
England
III
Idiopathic Pulmonary Fibrosis (IPF)
No match for these filter settings

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators. You may still be able to take part if studies aren't local to you. Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org. You may also request for a study to be added.

This page is under development. We welcome your feedback! Please email research@actionpf.org.

Are you a researcher currently recruiting participants in the UK? If you would like your study included on this page, please complete this online form.

Can't find anything that interests you? Check back soon as we regularly update these pages.